



1647 CPA \$

CONTINUED PROSECUTION APPLICATION (CPA) REQUEST TRANSMITTAL <small>Submit an original, and a duplicate for fee processing (Only for Continuation or Divisional applications under 37 CFR 1.53(d))</small>		<input type="checkbox"/> DUPLICATE
-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------	--	-------------------------------------------

Address to: Assistant Commissioner for Patents Box CPA Washington, DC 20231	Attorney Docket No.	9491-013-27
	First Inventor	CAMELLIA W. ADAMS, ET AL.
	Group Art Unit	1647
	Examiner	SPECTOR L.

This is a request for a ☒ continuation or ☐ divisional application under 37 CFR 1.53(d) (continued prosecution application (CPA)) of prior application number 09/138,091 filed on AUGUST 21, 1998 entitled AGONIST ANTIBODIES

1. ☐ Enter the unentered amendment previously filed under 37 CFR 1.116 in the prior nonprovisional application.

2. ☒ A preliminary amendment is enclosed.

3. ☐ This application is filed by fewer than all the inventors named in the prior application, 37 CFR 1.53 (d)(4)

a. ☐ DELETE the following inventor(s) named in the prior nonprovisional application:

b. ☐ The inventor(s) to be deleted are set forth on a separate sheet attached hereto.

4. ☐ A new power of attorney or authorization of agent (PTO/SB/81) is enclosed.

5. Information Disclosure Statement (IDS) is enclosed:

a. ☐ PTO-1449

b. ☐ Copies of IDS Citations

RECEIVED
SEP 12 2000
TECH CENTER 1600/2900
H/S
for 7/4

CLAIMS	NUMBER FILED		NUMBER EXTRA	RATE	CALCULATIONS
TOTAL	6	MINUS 20	0	× \$18 =	\$0.00
INDEPENDENT	1	MINUS 3	0	× \$78 =	\$0.00
		<input type="checkbox"/> MULTIPLE DEPENDENT CLAIMS		+ \$260 =	\$0.00
		BASIC FEE			\$690.00
		TOTAL OF ABOVE CALCULATIONS			\$690.00
		<input type="checkbox"/> Reduction by 50% for filing by Small Entity			\$0.00
TOTAL					\$690.00

6. Small Entity Status:

a. ☐ A small entity statement is enclosed.

b. ☐ A small entity statement was filed in the prior nonprovisional application and such status is still proper and desired.

c. ☐ Is no longer claimed.

7. ☒ The Commissioner is hereby authorized to charge fees under 37 CFR 1.16 and 1.17 for the papers being filed herewith and for which no check is enclosed, or credit any overpayment to Deposit Account No. 50-1442.

☒ If these papers are not considered timely filed by the Patent and Trademark Office, then a petition is hereby made under 37 CFR 1.136 for the necessary extension of time in the parent case. Any fees required for such an extension of time may be charged to Deposit Account No. 50-1442.

8. ☒ A check in the amount of \$690.00 is enclosed.

9. ☐ Other:

09/08/2000 CHNGUYEN 00000020 09138091

01 FC:131 690.00 OP

1200 Nineteenth Street, N.W.
Washington, D.C. 20036-2412
Telephone No. (202) 861-3900
Facsimile No. (202) 223-2085

Respectfully submitted,

PIPER MARBURY RUDNICK & WOLFE LLP

Steven B. Kelber
Registration No. 30,073

Amy L. Miller
Registration No. 43,804

Docket No. 9491-013-27



C/16/00
9/15/00

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE APPLICATION OF: CAMELLIA W. ADAMS, ET AL. GAU: 1647
SERIAL NO: 09/138,091 EXAMINER: SPECTOR, L.
FILING DATE: AUGUST 21, 1998
FOR: AGONIST ANTIBODIES

PRELIMINARY AMENDMENT

ASSISTANT COMMISSIONER FOR PATENTS
WASHINGTON, D.C. 20231

RECEIVED
SEP 12 2000
TECH CENTER 1600/2900

SIR:

Prior to examination of the above-identified application, and to advance the prosecution thereof, please amend the above-identified application in the following manner.

IN THE CLAIMS:

Please cancel Claims 1-42.

Please add the following new Claims 43-48.

- 43. An isolated nucleic acid encoding an agonist antibody, fragment, or variant thereof which binds to a thrombopoietin receptor.

44. The isolated nucleic acid of Claim 43, wherein said thrombopoietin receptor comprises mammalian c-mpl.

45. The isolated nucleic acid of Claim 44, wherein said thrombopoietin receptor is human c-mpl.

C/1 *Sub B1* 46. A vector comprising the nucleic acid of Claim 43.

47. A host cell comprising the vector of Claim 46.

48. A method of producing an agonist antibody comprising culturing the host cell of Claim 47 under conditions wherein the nucleic acid is expressed.- -